Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

NCT02723994 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02723994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02723994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2016
Completion date
March 3, 2026
Enrollment
171 (actual)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia